論文

国際誌
2022年9月

Improvement in Quality of Life via Catheter Ablation for Atrial Fibrillation in Patients Undergoing Hemodialysis Therapy.

CJC open
  • Masato Hachisuka
  • Hiroshi Hayashi
  • Yu-Ki Iwasaki
  • Nobuaki Ito
  • Toshiki Arai
  • Serina Kobayashi
  • Rei Mimuro
  • Yuhi Fujimoto
  • Eiichiro Oka
  • Kanako Hagiwara
  • Ippei Tsuboi
  • Hiroshige Murata
  • Teppei Yamamoto
  • Michio Ogano
  • Kenji Yodogawa
  • Meiso Hayashi
  • Wataru Shimizu
  • 全て表示

4
9
開始ページ
748
終了ページ
755
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.cjco.2022.05.009

BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia in patients undergoing hemodialysis (HD); AF lowers quality of life (QoL) and increases the risk of dialysis-related complications. The present study aimed to evaluate the effectiveness of AF ablation on the QoL in patients undergoing HD. METHODS: Nineteen patients undergoing HD (14 men, age 68 ± 8 years; 15 with paroxysmal AF) who underwent catheter ablation (CA) of AF were enrolled in the study. The Kidney Disease Quality of Life Short Form (KDQOL-SF) was assessed to evaluate the QoL of the HD patients at baseline and 6 months after the ablation. Ablation outcomes and procedural complications were evaluated and compared to those of 1053 consecutive non-HD patients who underwent AF ablation. RESULTS: The KDQOL-SF of the HD patients 6 months after the ablation showed an improvement in physical functioning (54 ± 23 to 68 ± 28, P < 0.01), general health perceptions (38 ± 17 to 48 ± 15, P < 0.01), and symptoms/problems (75 ± 21 to 84 ± 13, P = 0.02), compared to baseline. For intradialytic symptoms, dyspnea during HD significantly improved after the CA in the HD patients without AF recurrence (43% to 7%, P = 0.04), whereas the atrial tachyarrhythmias and hypotension during HD remained unchanged. During the follow-up period of 17 ± 13 months after the last procedure, the incidence of being arrhythmia-free was similar (HD patients, 79% vs non-HD patients, 86%, log-rank P = 0.82). No life-threatening complications occurred in any of the patients. CONCLUSIONS: CA of AF improves QoL in patients undergoing chronic HD therapy.

リンク情報
DOI
https://doi.org/10.1016/j.cjco.2022.05.009
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/36148254
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486863
ID情報
  • DOI : 10.1016/j.cjco.2022.05.009
  • PubMed ID : 36148254
  • PubMed Central 記事ID : PMC9486863

エクスポート
BibTeX RIS